{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Grade III-IV Acute GVHD by Day 100. The incidence of Gr III-IV acute GVHD was measured by the modified Glucksburg scale.","groups":[{"description":"Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.\n\nAbatacept: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.","id":"OG000","title":"Abatacept"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 100 post-transplant","title":"Percentage of Participants With Grade III-IV Acute GVHD by Day 100.","type":"PRIMARY","unitOfMeasure":"percentage of participants"}